Equities Analysts Offer Predictions for DYAI FY2026 Earnings

Dyadic International Inc. (NASDAQ:DYAI) – Analysts at Zacks Research decreased their FY2026 earnings per share estimates for Dyadic International in a report issued on Monday, March 30th. Zacks Research analyst J. Vandermosten now forecasts that the biotechnology company will earn ($0.12) per share for the year, down from their previous forecast of ($0.11). The consensus estimate for Dyadic International’s current full-year earnings is ($0.18) per share. Zacks Research also issued estimates for Dyadic International’s FY2027 earnings at ($0.16) EPS.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Dyadic International in a research note on Friday, March 27th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $3.00.

Dyadic International Stock Performance

Dyadic International stock opened at $0.85 on Wednesday. The company has a market cap of $31.05 million, a PE ratio of -3.41 and a beta of 1.21. The company has a current ratio of 2.68, a quick ratio of 2.68 and a debt-to-equity ratio of 4.08. Dyadic International has a 1 year low of $0.65 and a 1 year high of $1.43. The company’s 50-day moving average is $0.82 and its two-hundred day moving average is $0.94.

Dyadic International (NASDAQ:DYAI) last announced its quarterly earnings data on Wednesday, March 25th. The biotechnology company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.03). The firm had revenue of $0.57 million during the quarter, compared to analyst estimates of $1.34 million. Dyadic International had a negative return on equity of 695.96% and a negative net margin of 239.67%.

Hedge Funds Weigh In On Dyadic International

Institutional investors have recently modified their holdings of the business. Geode Capital Management LLC increased its stake in Dyadic International by 13.7% during the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after purchasing an additional 36,266 shares in the last quarter. Marathon Capital Management lifted its stake in Dyadic International by 142.9% in the fourth quarter. Marathon Capital Management now owns 85,000 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 50,000 shares in the last quarter. Apis Capital Advisors LLC acquired a new position in shares of Dyadic International in the third quarter valued at approximately $1,817,000. Landscape Capital Management L.L.C. acquired a new position in shares of Dyadic International in the third quarter valued at approximately $190,000. Finally, Truist Financial Corp increased its position in shares of Dyadic International by 30.5% during the third quarter. Truist Financial Corp now owns 326,200 shares of the biotechnology company’s stock worth $385,000 after acquiring an additional 76,200 shares in the last quarter. Institutional investors own 27.95% of the company’s stock.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.